Samsung Biologics Co.,Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was KRW 43,029.2 million compared to KRW 27,589.04 million a year ago. Net income was KRW 146,942.73 million compared to KRW 60,975.54 million a year ago. Basic earnings per share from continuing operations was KRW 2,221 compared to KRW 922 a year ago. Diluted earnings per share from continuing operations was KRW 2,218 compared to KRW 922 a year ago. Basic earnings per share was KRW 2,221 compared to KRW 922 a year ago. Diluted earnings per share was KRW 2,218.